Harmony Biosciences Holdings Executive Compensation
Harmony Biosciences announced the compensation terms for its leadership succession plan, including a separation and consulting agreement for retiring CEO Jeffrey M. Dayno and an amended employment agreement for incoming CEO Peter Anastasiou. Dr. Dayno will serve as a non-executive advisor through January 2028 at a rate of $500 per hour with continued equity vesting, while Mr. Anastasiou's new terms as President and CEO take effect January 1, 2027.
- Term
- through Jan 2028